From New York Post · · 1m
Breakthrough treatment for endometrial cancer
New drug reduces cancer spread and death for women with advanced endometrial cancer.
In brief
New drug reduces cancer spread and death for women with advanced endometrial cancer. Sacituzumab tirumotecan (sac-TMT) lowers recurrence and death risk for endometrial cancer patients by 41% and 32% respectively. Originally reported by New York Post.
New treatment for endometrial cancer
Researchers from NYU Langone Health and Perlmutter Cancer Center found a drug that lowers cancer recurrence and death risk.
Drug reduces cancer spread and death
The drug lowers recurrence risk by 41% and death risk by 32% for women with advanced endometrial cancer.
Drug shows positive responses
35% of women treated with the drug showed tumor shrinkage, more than twice the rate for standard chemotherapy.
Study principal investigator
Bhavana Pothuri says the drug is a new standard treatment for recurrent endometrial cancer.
Drug targets cancer cells
The drug attaches to Trop-2 protein on endometrial cancer cells to deliver targeted treatment.
Clinical guidelines to change
Pothuri recommends clinical guidelines for endometrial cancer will need to be updated to include the drug.
The key point
Sacituzumab tirumotecan (sac-TMT) lowers recurrence and death risk for endometrial cancer patients by 41% and 32% respectively.
